GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Accounts Payable

NBIO (Nascent Biotech) Accounts Payable : $0.68 Mil (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Accounts Payable?

Nascent Biotech's Accounts Payable for the quarter that ended in Jun. 2024 was $0.68 Mil.

Nascent Biotech's quarterly Accounts Payable increased from Dec. 2023 ($0.48 Mil) to Mar. 2024 ($0.69 Mil) but then declined from Mar. 2024 ($0.69 Mil) to Jun. 2024 ($0.68 Mil).

Nascent Biotech's annual Accounts Payable declined from Mar. 2022 ($0.78 Mil) to Mar. 2023 ($0.50 Mil) but then increased from Mar. 2023 ($0.50 Mil) to Mar. 2024 ($0.69 Mil).

Nascent Biotech Accounts Payable Historical Data

The historical data trend for Nascent Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Accounts Payable Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Accounts Payable
Get a 7-Day Free Trial 0.85 0.64 0.78 0.50 0.69

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.51 0.48 0.69 0.68

Nascent Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Nascent Biotech Accounts Payable Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nascent Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Accounts Payable
Comparable Companies
AIM NLSP ACST NTBL BIXT UNCY PIRS SKYE AURX ELEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Website
https://www.nascentbiotech.com
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121